Key result
Next-generation bioresorbable scaffolds require randomized trials to overcome first-generation limitations in coronary artery disease.
: Drawbacks of the first-generation BRSs need to be addressed by the next generation of these stents with novel materials and technologies. Clinical research, including randomized controlled trials, are required to further evaluate BRSs application in coronary artery disease. The encouraging results of BRSs innovation applied in the peripheral arteries and gastrointestinal tracts support other potential clinical applications of BRS technology.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2021) conducted a review in Coronary artery disease. Bioresorbable scaffolds (BRSs) was evaluated. Next-generation bioresorbable scaffolds require further randomized controlled trials to address first-generation drawbacks and evaluate their application in coronary artery disease.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: